LCG Bioscience Report issue

For profit Phase 1
Founded: Cambridge United Kingdom (1993)
Status: No NME R&D (1993)

Organization Overview

First Clinical Trial
2007
NCT01243502
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

LCG Bioscience, Bourn Hall, Bourn, Cambridgeshire, CB23 2TN, UK

Active Ingredients

Drugs in Phase 1 Trials (2)

ct327 (1 trial)

leo 29102 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 1)

Dermatitis, Atopic (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2